

Attorney Docket No. VPI/02-118 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/809,946
Confirmation No.: 6414
Filing Date: March 25, 2004
Examiner: Not yet assigned
Group Art Unit: 1624
Applicants: Brenchley et al.
For: THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES

August 26, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copy(ies) of references Citation No(s). A1, B1, B2, B3, C1 are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- ☒ A copy of the International Search Report received in the corresponding PCT Application No. US2004/009166 is attached herewith.

(b) ☒ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.


Applicants: Brenchley et al.
Application No.: 10/809,946

- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.


Applicants: Brenchley et al.
Application No.: 10/809,946

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,


Karen E. Brown, Reg. No. 43,866
Attorney/Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited
with the U.S. Postal Service as First Class Mail in an envelope
addressed to Commissioner for Patents, Mail Stop: Amendment,
P.O. Box 1450, Alexandria, VA 22313-1450 on 8-26-05



8-26-05

Date of Signature

16120-1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/809,946
	Filing Date	March 25, 2004
	First Named Inventor	Guy Brenchley
	Group Art Unit	1624
	Examiner Name	Not yet assigned
	Attorney Docket Number	VPI/02-118 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	US2003/119856 A1	6/26/2003	Harrington et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	00/78731 A1	Celltech Chiroscience Ltd.	28 December 2000		
	B2	WO	97/19065 A1	Celltech Therapeutics Ltd.	29 May 1997		
	B3	WO	02/096905 A1	Vertex Pharmaceuticals, Inc.	5 December 2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Strawn, Laurie et al., "Tyrosine Kinases in Disease: Overview of Kinase Inhibitors as Therapeutic Agents and Current Drugs in Clinical Trials", Expert Opinion on Investigational Drugs, Vol. 7, No. 4, Pages 553-573, (1998).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Our Docket No.: VPI/02-118 US




Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On August 26, 2005.
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (A1, B1-B3, C1); and
4. Return Postcard Receipt.


Signature

Lisa M. Romano
Typed or printed name of person signing Certificate